接受6个月促黄体生成素释放激素激动剂联合放疗的不利风险前列腺癌男性中抗雄激素使用时长与死亡风险
1995至2001年纳入206例不利风险前列腺癌男性的随机试验,比较放疗联合或不联合6个月雄激素剥夺治疗。102例随机至ADT者中29例部分使用第一代抗雄激素(中位4.2个月)。中位随访16.62年后156例死亡。在中重度合并症男性中,从无ADT到部分到全程ADT死亡增加(P=0.02),全程较部分抗雄激素使用全因死亡风险调整HR 2.25(95%CI 0.94-5.41;P=0.07)。
要点
- 中重度合并症男性从无ADT到部分到全程ADT死亡增加(P=0.02)。
- 中重度合并症男性全程较部分抗雄激素使用全因死亡调整HR 2.25(95%CI 0.94-5.41;P=0.07)。
- 无或轻微合并症男性全程较部分抗雄激素使用全因死亡调整HR 0.97(95%CI 0.49-1.91;P=0.92)。
核心结论
- 增加抗雄激素使用约2个月似乎不影响无或轻微合并症的局限不利风险前列腺癌男性生存,但可能缩短中重度合并症男性生存,引发对抗雄激素处方对象和时长的担忧。
研究设计与样本
- 1995至2001年纳入206例不利风险前列腺癌男性的随机试验,比较放疗联合或不联合6个月雄激素剥夺治疗。
- 102例随机至ADT者中29例部分使用第一代抗雄激素(中位4.2个月)。
- 采用Cox回归及Fine和Gray回归评估全程与部分抗雄激素使用对合并症亚组内前列腺癌特异性死亡和全因死亡风险的影响。
主要发现
- 中位随访16.62年后156例死亡。
- 中重度合并症男性中,从无ADT到部分到全程ADT死亡增加(P=0.02),全程较部分抗雄激素使用全因死亡调整HR 2.25(95%CI 0.94-5.41;P=0.07)。
- 中重度合并症男性中,部分抗雄激素使用组发生1例前列腺癌死亡,全程抗雄激素使用组无前列腺癌死亡。
- 无或轻微合并症男性中,全程较部分抗雄激素使用全因死亡调整HR 0.97(95%CI 0.49-1.91;P=0.92),前列腺癌特异性死亡调整HR 0.39(95%CI 0.07-52.18;P=0.28)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether adding a first-generation anti-androgen (AA) to a luteinizing hormone-releasing hormone agonist in the radiotherapeutic management of unfavorable-risk prostate cancer (PC) reduces the risk of all-cause and PC-specific mortality (ACM and PCSM) among men within differing comorbidity subgroups is unknown. METHODS: Between 1995 and 2001, 206 men with unfavorable-risk PC were enrolled in a randomized trial comparing radiation with or without 6 months of androgen-deprivation therapy (ADT). Partial AA use (median: 4.2 months) occurred in 29 of the 102 men randomized to ADT. Cox, and Fine and Gray's regressions were used to evaluate the impact of full versus partial AA use on PCSM and ACM-risk within comorbidity subgroups. RESULTS: After a median follow-up of 16.62 years, 156 men died. In men with moderate to severe comorbidity increasing death was observed as treatment transitioned from no to partial to full ADT (P=0.02) with an increased ACM-risk with full versus partial AA use (adjusted hazard ratio (AHR), 2.25 (95% confidence interval (CI), 0.94-5.41); P=0.07); whereas only 1 and no PC deaths occurred in men receiving a partial versus full AA course, respectively. Among men with no or minimal comorbidity there was no decrease in ACM (AHR, 0.97 (95% CI, 0.49-1.91); P=0.92) or PCSM-risk (AHR 0.39 (95% CI 0.07-52.18); P=0.28) in comparing full versus partial AA use. CONCLUSION: Increasing AA use by 2 months does not appear to impact survival in men with localized unfavorable-risk PC and no or minimal comorbidity, but may shorten survival in men with moderate to severe comorbidity, raising concern regarding in whom and for how long the AA should be prescribed.
引用
- Sanford NN, Chen MH, Loffredo M, et al. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death. Prostate Cancer Prostatic Dis. 2016. PMID: 27824043. doi:10.1038/pcan.2016.53
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。